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Mycoplasma pneumoniae (Mp) is a leading cause of community acquired pneumonia.
Knowledge regarding Mp pneumonia obtained from animal models or human subjects has
been discussed in many different reports. Accumulated expertise concerning this critical
issue has been hard to apply clinically, and potential problems may remain undiscovered.
Therefore, our multidisciplinary team extensively reviewed the literature regarding Mp
pneumonia, and compared findings from animal models with those from human subjects.
In human beings, the characteristic pathological features of Mp pneumonia have been
reported as alveolar infiltration with neutrophils and lymphocytes and lymphocyte/plasma
cell infiltrates in the peri-bronchovascular area. Herein, we demonstrated the novel aspects
of Mp pneumonia that the severity of the Mp pneumonia seemed to depend on the host
innate immunity to the Mp, which might be accelerated by antecedent Mp exposure
(re-exposure or latent respiratory infection) through up-regulation of Toll-like receptor
2 expression on bronchial epithelial cells and alveolar macrophages. The macrolides
therapy might be beneficial for the patients with macrolide-resistant Mp pneumonia via
not bacteriological but immunomodulative effects. This exhaustive review focuses on
pathogenesis and extends to some therapeutic implications such as clarithromycin, and
discusses the various diverse aspects of Mp pneumonia. It is our hope that this might
lead to new insights into this common respiratory disease.
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INTRODUCTION
Mycoplasma pneumoniae (Mp) was first isolated in tissue culture
from the sputum of a patient with primary atypical pneumonia
by Eaton et al. (1944). This “Eaton’s agent” was shown to be a
Mycoplasma species in 1961. Chanock et al. succeeded in cultur-
ing Eaton’s agent in mammalian cell-free medium and proposed
the taxonomic designation Mp in 1963 (Chanock et al., 1962;
Chanock, 1963). Mp is a unique organism that lacks a cell wall in
any circumstances, and does not need a host cell for replication.
This organism causes a variety of clinical presentations, from self-
limiting to life-threatening. The disease severity seems to depend
on the degree of host’s defenses. In this review, we focused on
the pathogenesis of Mp pneumonia from the perspective of host
defenses, based on findings from our mouse models.
EPIDEMIOLOGY
Mp is one of the most common pathogens of community-
acquired pneumonia (CAP) in adults (Table 1). In general, both
regional differences and varying periods of surveillance may
influence the results of etiological studies of infectious diseases.
Table 1 summarizes the proportions of adult Mp pneumonia
among CAP populations enrolled in several large-scale studies
conducted in various countries (Marston et al., 1997; Ngeow
et al., 2005; Arnold et al., 2007; Von Baum et al., 2009; Cilloniz
et al., 2011). Mp pneumonia accounted for 10.6–17.0 and 3.0–
20.8% of CAP in out- or in-patients settings, respectively, and the
frequency of ICU admission was relatively low (2–3.6%). Arnold
et al. showed that Mp is the most common atypical pneumo-
nia pathogen, accounting for 11–15% of CAP throughout the
world (Arnold et al., 2007). Serological studies in Denmark over a
50-year period showed that Mp infections exhibit epidemic peri-
odicity every 3–5 years, but this trend now seems to be getting
obscured (Lind et al., 1997). Mp pneumonia occurs at any age,
but the incidence is less common in elderly, as compared with
young, adults (Lim et al., 2009), and is highest among school-aged
children (Foy et al., 1979).
Macrolides were recommended for treatment of microbio-
logically defined Mp pneumonia. However, macrolide-resistant
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Table 1 | Prevalence ofMycoplasma pneumoniae pneumonia in CAP.
Author Country Year N Out-Pts% Ward% ICU% Total% Mortality%
Cilloniz Spain 1996–2008 1463 17 3 2 4 3.1
Ngeow Asia 2001–2002 926 ND ND 3.6 11.4 ND
Baum German 2002–2006 4532 10.6 4.7 6.8 0.7
Marston USA 1991 1938 ND 20.8** (5.4*) 20.8* (5.4*) ND
Arnold Whole world 2001–2006 4337 ND 12 12 ND
(Marston et al., 1997; Ngeow et al., 2005; Arnold et al., 2007; Von Baum et al., 2009; Cilloniz et al., 2011).
*definite case.
**definitive and possible cases.
N, number; ND, not determined; Out-Pts, out patients.
Mp was isolated from Japanese children, and the incidence was
increasing in the early 2000s (Matsuoka et al., 2004). There
was a major concern that macrolide-resistant Mp had increased
locally and was spreading throughout the world. In East Asia,
macrolide-resistant Mp rapidly increased and became the cause
of the majority of clinically-proven Mp in both children and
adults. The prevalence of macrolide-resistant Mp varies among
countries and age groups (Averbuch et al., 2011; Akaike et al.,
2012; Miyashita et al., 2012; Spuesens et al., 2012; Uldum et al.,
2012; Yamada et al., 2012; Yoo et al., 2012; Dumke et al., 2013;
Eshaghi et al., 2013; Pereyre et al., 2013; Wu et al., 2013; Zhao
et al., 2013) (Table 2). For example, over 90% of isolated Mp in
China was macrolide resistant, while no macrolide-resistant Mp
was found in the Netherlands. Generally, it became highly preva-
lent in East Asian countries including China, Japan and South
Korea, while being a medium or low prevalent in North America
and Europe, respectively. Macrolide-resistant Mp is reportedly
more prevalent in children, and the predominant point mutation
found was A2063G in domain V of 23S rRNA. Aside from geo-
graphical and racial differences between individual studies, the
application of different diagnostic techniques or criteria might
affect the epidemiology of Mp pneumonia in each study.
HUMAN PATHOLOGY AND BRONCHOALVEOLAR LAVAGE
FLUID
PATHOLOGY
Studies focused on the pathological description of human Mp
pneumonia have rarely been reported. However, pathological
examinations have been conducted on several different types of
specimens that were sampled using different techniques; e.g.,
autopsy specimens (Parker et al., 1947; Maisel et al., 1967; Benisch
et al., 1972; Meyers and Hirschman, 1972; Halal et al., 1977;
Kaufman et al., 1980; Koletsky and Weinstein, 1980), open lung
biopsy specimens (Coultas et al., 1986; Rollins et al., 1986; Llibre
et al., 1997; Ebnother et al., 2001; Wachowski et al., 2003),
video-assisted thoracic surgery (VATS) specimens (Chan et al.,
1999) and transbronchial lung biopsy specimens (Ganick et al.,
1980; Nakajima et al., 1996; Ohmichi et al., 1998). According
to these reports, the most characteristic pathological feature of
human Mp pneumonia is a marked plasma cell-rich lymphocytic
infiltration in the peri-bronchovascular areas (PBVAs), with accu-
mulations of macrophages, neutrophils, and lymphocytes in the
alveolar spaces (Parker et al., 1947; Coultas et al., 1986; Rollins
Table 2 | Proportions of macrolide-resistantMycoplasma pneumonia.
et al., 1986). The presence of plasma cells in PBVAs might reflect
up-regulation of humoral immunity via Mp infection.
BRONCHOALVEOLAR LAVAGE FLUID (BALF) FINDINGS
There have been several case series focused on BALF obtained
from human Mp pneumonia patients (Hayashi et al., 1986, 1993,
1998; Yano et al., 2001); those studies demonstrated varying levels
of monocytes, polymorphonuclear leukocytes (PMNs), lympho-
cytes, eosinophils, and total cell counts. Among them, PMNs and
lymphocytes counts were relatively more increased than the other
cell types. The CD4 to CD8 ratios in the BALF were also elevated,
and ranged from 2.1 (Hayashi et al., 1986) to 3.5 ± 2.1 (Hayashi
et al., 1993), irrespective of the sampling timing.
PATHOGENESIS
ANIMAL MODELS
The incidence of Mp pneumonia is relatively low among the
elderly over 70 years old or children less than 5 years old. This
led to the hypothesis that elderly persons must be repeatedly
exposed to and respond immunologically to the organism with
clinical or subclinical progression. Indeed, as for cellular immu-
nity, Brunner et al. have suggested that the occurrence of clinical
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disease in adults is favored by prior sensitization induced by infec-
tion at an early age, causing large or small mononuclear cell
reactions (Brunner et al., 1973). This cellular response, lasting
several years, could be proved by Mp antigen-induced lympho-
cyte transformation of cell suspensions from previously infected
patients (Biberfeld et al., 1974; Biberfeld, 1974). It is impor-
tant for us to understand immune responses attributed to Mp
pneumonia.
We designed five different mouse models for Mp pneumonia
(Figure 1) to examine the resulting pathology in animals hav-
ing various immune status (Saraya et al., 2007b, 2011; Saraya,
2013). Animals were peritoneally immunized with various regi-
mens (one per model) once a week (on days −14 and −7), then
1 week after the last immunization the animals were intratra-
cheally (IT) challenged with sonicated Mp antigen, as previously
reported (Saraya et al., 2011). Among those models, only groups
immunized with Mp antigen and alum adjuvant (Figure 1E) or
CpG (Figure 1C) developed severe lymphocytic infiltration into
PBVAs at 96 h after IT (Figures 2C,E) while, no inflammatory
cells were seen on models A and B (Figures 2A,B). However, the
pathognomonic feature for human Mp pneumonia was recon-
structed only in models D and E, in which lymphoplasmacytic
infiltration into PBVAs occurred 96 h post-IT (Figures 2D,E).
Those results suggest that enhanced host immune responses, as
occurred in models C and E, against Mp antigen are required for
persistent inflammation in the lung, as well as Th2 characteristics
(produced by use of Th2 adjuvant, as in models D and E) causing
plasma cell infiltration into the PBVAs, but not Th1 characteris-
tics (produced by use of the Th1 adjuvant, CPG, as in the model
depicted in Figure 1C). Aluminum hydroxide adjuvant, named
alum, is well-known for initiating strong antigen-specific Th2
responses in the absence of interleukin(IL)-4- or IL-13-mediated
signaling (Brewer et al., 1999); Th2 predominant characteris-
tics might be required to generate typical Mp pneumonia, even
in humans. Previous studies showed that the histopathologi-
cal score of Mp pneumonia is significantly higher in infected
BALB/c mice (Th2 predominant) than in C57BL/6 mice (Th1
predominant) through the late phase, suggesting differences in
host reactions against intranasally-inoculated live Mp (Fonseca-
Aten et al., 2005). Tanaka et al. (1996) describe the different
pathological findings in an M. pulmonis–infected mouse model
for treatment with IL-2 (Th1 up-regulated) vs. cyclosporine A
(Th1 down-regulated).
Thus, the severity of Mp pneumonia seems to depend on
the host immune response to the infection through a complex-
ity of various mechanisms, including an allergic reaction to Mp,
Mp virulence, host defenses, and polarization toward Th1 or
Th2 predominance, to name a few. In the context of allergic
reaction, IgE antibodies specific to Mp were detected in serum
samples from patients with Mp pneumonia, suggestive of IgE-
mediated hypersensitivity (Tipirneni et al., 1980; Yano et al., 1994;
Seggev et al., 1996) as well as an involvement in asthma attacks
(Henderson et al., 1979; Biscardi et al., 2004). In this review,
we will further discuss the pathomechanisms of Mp pneumo-
nia from the perspective of the virulence of Mp and presumed
host defenses based on findings obtained from our experimental
mouse models.
FIGURE 1 | Female BALB/c (7-week-old) mice were inoculated
intratracheally with Mp antigen with or without pre-immunization.
Pre-immunization was carried out by intraperitoneal injection at 7 and 14
days prior to the intratracheal (IT) challenge. Model A: IT without
pre-immunization. Model B: IT after twice pre-immunizing with Mp antigen
alone. Model C: IT after twice pre-immunizing with Mp antigen plus CpG.
Model D: IT after twice pre-immunizing with alum alone. Model E: IT after
twice pre-immunizing with Mp antigen plus alum. One week following the
last immunization, mice underwent IT with 50μg of Mp antigen.
Bronchoalveolar lavage fluid (BALF) and lung specimens were obtained
before this process and 8, 24, 48, 96, and 168 h after IT. Mp: mycoplasma.
VIRULENCE OF MP
Lipoproteins
Lipoproteins from various Mycoplasma species have potent
inflammatory properties. Three lipoproteins/lipopeptides of M.
fermentans origin, macrophage-activating lipopeptide-2 (MALP-
2), P48, andM161Ag (identical to MALP-404), reportedly modu-
late the host immune system via Toll-like receptor (TLR)-2/TLR-6
signaling (Takeuchi et al., 2000; Luhrmann et al., 2002; Seya and
Matsumoto, 2002). Genes for more than 30 different Mp lipopro-
teins have been reported (Himmelreich et al., 1997). Shimizu et al.
reported that the mycoplasma-derived lipoproteins N-ALP1/N-
ALP2 (Shimizu et al., 2008) and F0F1-ATPase (Shimizu et al.,
2005) activated NF-kβ via TLR-1, 2 or TLR-1, 2, 6 signaling,
respectively. Stimulation of these TLRs has been known to be
related to production of chemokines (Brant and Fabisiak, 2008;
Andrews et al., 2013) that promote lymphocyte and neutrophil
trafficking and inflammation in the lung.
CARDS (Community Acquired Respiratory Distress Syndrome) toxin
Kannan et al. first demonstrated the possibility that Mp pro-
duces the CARDS toxin that is involved in the mediation of
disease (Kannan et al., 2005). The CARDS toxin is an ADP-
ribosylating and vacuolating toxin, with homology to the S1
subunit of pertussis toxin, that has a high affinity for surfac-
tant protein-A, suggesting a physiological role for the toxin in
the pulmonary compartment. In mice, intranasal inoculation
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FIGURE 2 | Histopathological examination of lung specimens. At 96 h
post-intratracheal (IT) challenge, no inflammatory cells were seen in model
(A) A or (B) B specimens. Mild to moderate lymphocyte infiltration was
observed in the peribronchovascular area (PBVA) of (D) model D tissue.
Models (C) C and (E) E had more severe lymphocyte infiltration in the
PBVA. Plasmacyte infiltration within the PBVA was only recognized in
models D and E, and the number of infiltrating plasmacytes was
significantly higher in model E than model D. (F) High power magnification
of E. Hemotoxylin and eosin stain. A–F, 200x; E, 400x.
of recombinant CARDS toxin caused an increased level of pro-
inflammatory cytokines IL-1α, 1β, 6, 12, 17, Tumor necrosis
factor(TNF)-α, and Interferon-gamma (IFN) -γ together with
elevation of Keratinocyte chemoattractant(KC), IL-8, regulated
on activation, normal T cell expressed and secreted (RANTES),
and G-CSF (Hardy et al., 2009). However, to our knowledge,
there have been no reports of CARDS toxin identified in human
respiratory specimens.
Other factors
Mp produces a soluble hemolysin (Somerson et al., 1963,
1965), hydrogen peroxide and superoxide radicals, which pro-
duce oxidative stress in the respiratory epithelium, result-
ing in both structural and functional deterioration of cilia
(Waites and Talkington, 2004). Stimulation of human respira-
tory epithelial cells (A549 cells) in vitro with Mp lysate (MPL)
induced IL-8 production (Sohn et al., 2005). MPL induced
IL-8 release in a time- and dose-dependent manner together
with activation of extracellular signal-regulated kinase (ERK),
which was inhibited by PD98059, a specific inhibitor of ERK.
Chmura et al. (2003) reported that the Mp membrane frac-
tion induced IL-8 on BEAS-2B human bronchial epithelial cells.
Our report (Hirao et al., 2011) also demonstrated activation
of mitogen-activated protein kinase (MAPKs) on the alveolar
macrophage-like cell line, RAW264.6, by stimulation with Mp
antigen, as confirmed by significant suppression of IL-6 and
TNF-α production after preceding treatment with an MAPKs
inhibitor such as parthenolide (PAR: NF-kB inhibitor), SB20580
(SB, p38-linked signal of inhibitor), or LY294002 (LY, PI-3K
inhibitor). Thus, Mp antigen or live Mp can induce inflam-
matory cytokines in bronchial epithelial cells and in alveolar
macrophages (AMs).
HOST DEFENSES
Cellular immunity
Biberfeld et al. reported that the peripheral lymphocyte response
to a sonicate of Mp organisms or a membrane fraction was sig-
nificantly higher in recently infected patients than in healthy
patients (Biberfeld et al., 1974). The positive responsiveness to
sonicatedMp antigen was demonstrable up to 10 years after infec-
tion. Others also reported on the in vitro response of human
peripheral lymphocytes to Mp antigen (Fernald, 1972; Biberfeld,
1974), while tuberculin anergy in patients with Mp pneumo-
nia was noted soon or fairly soon after onset. This has been
speculatively explained by the possibility that (1) lymphocytes
and macrophages needed for the skin reaction to tuberculin
are engaged in the immune response to the infecting agent,
or (2) a transient change of the T lymphocyte population
occurs (Biberfeld and Sterner, 1976). Tanaka et al. reported that
the rate of positive tuberculin tests during the acute stage of
Mp pneumonia was higher in patients with the nodular type
of pulmonary lesions on thoracic computed tomography than
those having the consolidation pattern. This finding suggests
that the level of current cell-mediated immunity might influ-
ence the pattern of pulmonary lesions. Another study showed
that delayed hypersensitivity was noted on skin testing with
Mp antigen of patients with Mp pneumonia (Mizutani et al.,
1971).
However, to our knowledge, no direct evidence from patients
with Mp pneumonia has been reported regarding the reactivity
of BALF lymphocytes to Mp antigen. In other words, it is still
under debate whether the lung inflammation of Mp pneumonia
is a specific reaction to the Mp antigen.
In consideration of this question, Saraya et al. (2011)
demonstrated a lack of specific response of lymphocytes
in the BALF to Mp antigen 96 h post-IT using the 3H-
thymidine uptake test in an Mp pneumonia mouse model
(Figures 1D,E). The BALF cells in the lymphocyte gate
were 35.8% CD3 positive and 57.6% CD3 negative. Among
the CD3 positive cells, CD4−/CD8− cells were predom-
inant. The CD4 to CD8 ratio was 0.02, which was a
lower value than that of human Mp pneumonia patients
(Hayashi et al., 1986, 1993), and the CD8 positive cells con-
sisted of naïve cells (CD62L+hi/ CD44+lo), effector mem-
ory cells (CD62L+lo/CD44+hi), and central memory cells
(CD62L+hi/CD44+hi), in that order (Saraya et al., 2007a)
(Figure 3). Cellular immunity seemed to play an important
role in development of Mp pneumonia (Foy et al., 1973;
Broughton, 1986); the results given above might indicate that
non-specific reactions to Mp antigen govern the severity of lung
inflammation.
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FIGURE 3 | Flow cytometry analyses of CD3 positive lymphocytes from
the BALF of models D () and E () at 96h post-intratracheal
challenge. CD8-positive cells predominated, and consisted of naïve cells
(CD62L+hi/ CD44+lo), effector memory cells (CD62L+lo/CD44+hi), and
central memory cells (CD62L+hi/CD44+hi), in descending order.
Humoral immunity
The humoral immune responses in Mp pneumonia were
elucidated by the discovery of autoimmune-mediated phenom-
ena involving cross-reactive antibodies to host organs. Neurologic
manifestations following Mp infection can occur as a result of
molecularmimicry by carbohydratemoieties of the abundant gly-
colipids in the Mp membrane and the lipoglycan capsule (Ang
et al., 2002; Yuki, 2007). Autoimmune hematologic disorders can
also occur following Mp infection—transient brisk hemolytic
anemia, termed “paroxysmal cold hemogloblinuria.” As for lung
inflammation, how humoral immunity contributed to Mp pneu-
monia was unknown. However, patients with humoral deficiency
seemed to become chronic carriers of Mp (Taylor-Robinson
et al., 1980) or to undergo repeated episodes of Mp pneumonia
(Roifman et al., 1986) or severe arthritis (Taylor-Robinson et al.,
1978; Johnston et al., 1983), phenomena indicating that humoral
immunity plays a role in protection against these organisms.
Cytokine profile in blood and BALF
Cytokines are important components of the lung defense mech-
anism and inflammation (Yang et al., 2004). Here we describe
findings obtained from human patients and mouse models of Mp
pneumonia.
Cytokines in BALF of human Mp pneumonia. A few studies have
been reported concerning cytokine profiles in the BALF of human
Mp pneumonia patients. Koh et al. reported that IL-4 levels and
IL-4/IFN-γ ratios in BALF are significantly higher in children
with Mp pneumonia than in patients with pneumococcal pneu-
monia or control participants (Koh et al., 2001). This suggests
that a Th2-like cytokine response in Mp pneumonia is predomi-
nant, representing a favorable condition for IgE production. Yano
et al. described an increased level of eosinophil cationic protein
in BALF of all 10Mp pneumonia patients studied, supporting the
allergic aspects of Mp pneumonia (Yano et al., 2001).
Cytokine profile of BALF in Mp pneumonia mouse models.
Previous reports of mice inoculated with live Mp described that
Mp induced an increase in BALF of the concentrations of IL-17,
KC, TNF-α, IL-6, IFN-γ, and IL-12 (Fonseca-Aten et al., 2005;
Chu et al., 2006; Salvatore et al., 2007, 2008; Wu et al., 2007).
Likewise, we demonstrated that our model E (Figure 1) mice
had a significant increase in the levels of BALF cytokines, includ-
ing IL-6, MCP-1, and RANTES, 24 h post-IT, when compared to
those of model D mice (Figure 1) (Saraya et al., 2011), which
was thought to be attributable to antecedent immunization with
Mp antigen. Regarding the allergic aspect, Mp infection in air-
way epithelial cells can contribute to the pathogenesis of chronic
asthma by inducing RANTES and tumor growth factor-β1 (Sohn
et al., 2005). We also generated another mouse model (in which
no adjuvant was used), as reported by Kurai et al. (2013a), in
whichmice were intraperitoneally immunized with onlyMp anti-
gen twice, on day −28 and day −21 (RI, repeated inoculation,
group) or had no pretreatment (SI, single inoculation, group),
followed by IT challenge with Mp antigen on day 0 for both
groups (Figure 4). In this RI model, the levels of proinflamma-
tory or Th2 cytokines in BALF, including IL-17, KC, IL-6, TNFα,
and IL-4, were significantly higher than those of the SI model
mice. Furthermore, immunohistochemical analysis of lung tissues
collected on day 1 revealed IL-23 positive alveolar macrophages
together with elevation of IL-17 both in the BALF and in the
supernatants of lung-derived cells cultured with Mp antigen,
which suggested activation of the IL-23/IL-17 axis (Iwakura and
Ishigame, 2006). Likewise, Wu et al. reported that Mp infection
of mouse lungs can be prolonged when IL-23 mediated IL-17
production is neutralized (Wu et al., 2007).
Cytokine profile of blood in human Mp pneumonia. Tanaka
et al. reported that serum levels of IL-18 were elevated during
the acute phase of Mp pneumonia (Tanaka et al., 2002), which
suggested IL-18 and Th1 cytokines may play a significant role in
the immunopathologic responses in Mp pneumonia. Conversely,
other reports described polarization to Th2 in Mp pneumonia,
because of increased levels of eosinophil cationic protein (63%,
17 of 27 cases) (Yano et al., 2001) or the detection of IgE antibody
specific for Mp (Tipirneni et al., 1980; Yano et al., 1994; Seggev
et al., 1996), indicating an allergic aspect of human Mp pneumo-
nia. Esposito et al. reported that children with acute Mp infection
and wheeze had higher IL-5 concentrations than did healthy con-
trols (Esposito et al., 2002). Matsuda et al. reported that serum
IFN-γ, IL-6, and IP-10 (Interferon γ-induced protein 10) lev-
els were higher in patients infected with macrolide-resistant Mp
genotypes than were those in patients infected with conventional
Mp strains (Matsuda et al., 2013).
What are the key players leading to lung inflammation in Mp
pneumonia?
We have postulated a process for the generation of human Mp
pneumonia, which is described in Figure 5 and in the following
sections.
Bronchial epithelial cells. Mp attaches to ciliated respiratory
epithelial cells at the base of the cilia by means of a complex ter-
minal organelle at one end of the elongated organism, which is
mediated by interactive adhesins and accessory proteins clustered
at the tip of the organelle. Briefly, Mp attaches to the bronchial
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FIGURE 4 | The“noadjuvantused”modelwascreatedby intraperitoneally
immunizing with only Mp antigen twice, on days−28 and−21 (for the RI,
repeated inoculation, group) or without pre-treatment (for the SI, single
inoculation, group), followed by intratracheal challenge with Mp antigen
at day 0 for both groups. Those two models were evaluated at days 0, 1 2, 3,
4, and 7 by examination of bronchoalveolar lavage fluid or lung pathology.
epithelial cells via P1 adhesin (Razin and Jacobs, 1992), P30, and
other structures (HMW1, HMW2, HMW4, HMW5, P90, and
P65) (Waites and Talkington, 2004). Mp produces hydrogen per-
oxide and superoxide radicals, which induce oxidative stress in the
respiratory epithelium. Dakhama et al. reported that Mp upregu-
lated transforming growth factor (TGF)-β1 in primary cultures of
normal human bronchial epithelial cells (NHBE), and RANTES
in small airway epithelial cells (SAEC) (Dakhama et al., 2003),
which would act in vivo together with increased IL-8 production
on bronchial epithelial cells (Sohn et al., 2005).
Alveolar macrophages. First, Mp attaches to the bronchial epithe-
lial cells. Next, macrophages, including AMs, would play a role
as an innate host defense mechanism; however, to our knowl-
edge there are no reports regarding the number of macrophages
recruited or pre-existing in the bronchial lumen. AMs are the
predominant macrophage type in the lung, constituting approxi-
mately 93% of the pulmonary macrophage population (Marriott
and Dockrell, 2007). AMs originate from monocytes recruited
from the blood, but replication of AMs makes a minor contri-
bution to the total pool (Blusse Van Oud Alblas et al., 1981).
In Mp pneumonia, it has been reported that TLR-2 signal-
ing is involved in inflammatory cell activation by Mp-derived
lipoproteins (Shimizu et al., 2008). Chu et al. demonstrated that
expression of TLR-2 mRNA and protein on alveolar macrophages
and the recruitment of adaptor protein MyD88 increase after Mp
infection (Chu et al., 2005). AMs are early effectors of innate
immunity against any bacteria, and Mp was recognized via TLR1,
2, and 6 on AMs. Previously, studies using our models of germ-
free (Hayakawa et al., 2002) and other gnotobiotic mice (Sekine
et al., 2009), as well as another study by Chu et al. using BALB/c
and C57BL/6 mice (Chu et al., 2006), in turn demonstrated
that pre-immunization with live Mp or Mp antigen significantly
augmented inflammatory responses after the second challenge.
Likewise, Saraya et al. showed enhanced expression of TLR-2 on
bronchial epithelial cells and AMs after two immunizations with
Mp antigens plus adjuvant alum (Figures 1E, 2E,F) (Saraya et al.,
2011; Saraya, 2013). Based on those animal model studies, it is
likely that subclinical, latent infection with Mp in the lower res-
piratory tracts may up-regulate TLR-2 expression on AMs and
bronchial epithelial cells, which augments Mp reactivity.
AMs can also secrete proinflammatory cytokines (IL-6,
TNF-α, and IL-1β), IL-18, MIP-1α, KC, RANTES, IL-12, IL-
23, and MCP-1 (Saraya et al., 2011; Kurai et al., 2013a; Narita
et al., 2000), which are associated with neutrophilic infiltration.
Although the number of AMs after two immunizations (mod-
els D and E, Figures 1D,E) was equal, we demonstrated that the
accumulation of abundant neutrophils in the alveolar spaces as
early as 8 h post-IT in model E (Figure 1E) was attributable to
the effect of antecedent immunization with Mp antigen, as com-
pared with model D animals (Figure 1D) (Saraya et al., 2011).
Vigorous recruitment of neutrophils is one of the most important
components of the initial innate immune response (Craig et al.,
2009). Immunohistochemical analysis at 8 h post-IT of Model
E (Figure 1E) showed that AMs secreted RANTES, which is a
known, potent chemoattractant for neutrophils or lymphocytes.
However, abundant recruited neutrophils in the alveolar spaces
did not produce RANTES (Figure 6A). Bronchial epithelial cells
were also immunohistochemically stained with RANTES at 48 h
post-IT (Figure 6B).
In this regard, our mouse models for Mp pneumonia
(Figure 1E) indicated the possibility that even in humans, latent
respiratory infection might trigger the inflammation or enhance
the host defense through up-regulation of TLR-2 expression on
bronchial epithelial cells and AMs, followed by production of IL-
23-dependent IL-17 production (Wu et al., 2007; Kurai et al.,
2013a) or other chemokines, including RANTES.
Lymphocytes.Asmentioned above in the Section “Host defenses,”
for human Mp pneumonia, to our knowledge, no data are
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FIGURE 5 | Postulated schema for pathogenesis of human Mp
pneumonia. CARDS, Community Acquired Respiratory Distress Syndrome;
TNF, tumor necrosis factor; RANTES, regulated on activation; normal T cell
expressed and secreted; MCP-1, monocyte chemotactic protein-1.
FIGURE 6 | Immunohistochemical staining with RANTES at 8h and
48h post-IT challenge. (A) AMs secreted RANTES as early as 8 h after IT
challenge; abundant recruited neutrophils in alveolar spaces did not produce
RANTES. (B) Bronchial epithelial cells positive for RANTES at 48 h post-IT.
available regarding whether the presence of lymphocytes in the
lung or BALF is due to a specific reaction to Mp. Regarding
memory T cells, no combination of chemokine receptors and/or
adhesion molecules has apparently been identified to date that
imparts a preferential migration to the bronchial compartment or
alveolar compartment (Pabst and Tschernig, 1995; Wardlaw et al.,
2005; Kohlmeier and Woodland, 2006). Lymphocytes constitute
about 10% of all cells in the BALF of healthy adults. Less than 10%
of the lymphocytes in the BALF are B cells, and among the T cells,
CD4+ cells outnumber CD8+ cells (Pabst and Tschernig, 1997),
with a CD4+/CD8+ ratio of 1.7 (Pabst and Tschernig, 1995).
There are more so-called “memory” (>85%) than “naive” T lym-
phocytes in the BALF, which is different from the composition of
lymphocytes in other lung compartments (Pabst and Tschernig,
1997). Studies using our mouse model E (Saraya et al., 2011)
showed that CCL5 (also known as RANTES) was highly expressed
in lung cells, including bronchial epithelial cells, AMs, and lym-
phocytes. RANTES is produced by activated T cells, fibroblasts,
platelets, kidney epithelial cells, macrophages, and endothelial
cells, and is chemotactic for memory T cells, monocytes, and
eosinophils (Schall et al., 1990; Alam et al., 1993; Monti et al.,
1996) as well as neutrophils (Pan et al., 2000), triggering its recep-
tor, CCR5 (Charo and Ransohoff, 2006). Use of our model E
demonstrated CCR5-positive lymphocytes in the PBVA, implicat-
ing the contribution of RANTES in lung inflammation. Thus, as
mentioned in the “Host defenses” Section above, various proin-
flammatory cytokines and C-C chemokines (RANTES, MCP-1)
(Gunn et al., 1997; Johnston et al., 1999) might be key players in
the development ofMp pneumonia, both in the acute and chronic
phases (Conti and Digioacchino, 2001). Of note, lung pathology
seemed to differ according to host characteristics (Th1, Th2, and
Th17) which might be a non-specific reaction to Mp.
CLINICAL FEATURES
GENERAL ASPECTS
Mp infection is usually self-limited and rarely fatal. Mp infec-
tion causes both upper and lower respiratory infections, and
pneumonia occurs in 3–13% of infected persons (Clyde, 1993).
Clinical features of Mp infection vary among different ages, in
that patients under 2 years of age tend to have upper respira-
tory infections, while 6-19-year-olds tend to have pneumonia
(Foy et al., 1966; Denny et al., 1971). Two major subtypes of
the P1 gene are known to occur in Mp, and this subtype shift
phenomenon may have a relation to Mp pneumonia outbreaks
(Kenri et al., 2008). The severity of Mp pneumonia seems to
depend on theMp bacterial load rather thanMp subtype (Nilsson
et al., 2010). The incubation period for Mp infection is about
2–4 weeks, and characteristic findings of adult Mp pneumo-
nia are younger age, fewer comorbid diseases, shorter length of
stay in hospital, and lower mortality than any other group of
CAP patients. Prospective studies of patients withMp pneumonia
from Germany (Von Baum et al., 2009) and Japan (Goto, 2011)
revealed average (mean ± SD) ages of 41 ± 16 and 37.7 ± 16.6,
respectively.
Severity scores are widely used for assessing the requirement
for admission or when describing mortality rates, including the
pneumonia severity index (PSI) or CURB-65 (Cilloniz et al.,
2011). Gradual onset of respiratory or constitutional symptoms
such as cough, fever, headache, and malaise are relatively com-
mon symptoms in Mp pneumonia. In particular, dry cough
was usually observed in patients during early-phase Mp pneu-
monia, but it persists for a long period as a typical symptom.
Goto (2011) reported that the mean body temperature in adult
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Japanese patients with Mp pneumonia was 37.7 ± 1.0◦C and
that 29.2% of patients had a temperature no greater than 37.0◦C.
Analysis of physical examination data revealed thatmore than half
of patients with Mp pneumonia had no audible crackles and were
likely to have late-inspiratory crackles as compared with those
infected with typical pathogens (Norisue et al., 2008). On labo-
ratory examination, Mp pneumonia patients had relatively lower
leukocyte counts than did those having pneumonia from other
causes (Von Baum et al., 2009).
Macrolide was not the preferable treatment for S. pneumoniae
pneumonia, as opposed to pneumonia from atypical pathogens,
including Mp because highly macrolide-resistant Streptococcus
pneumoniae was emerging to become dominant in Japan (Goto
et al., 2009). The Japanese Respiratory Society (JRS) recom-
mended discrimination of atypical pneumonias from CAP due
to other pathogens (Committee For The Japanese Respiratory
Society Guidelines For The Management Of Respiratory, 2006),
and proposed six characteristic signs and symptoms of Mp pneu-
monia that can easily discriminate the two. Indeed, Yin et al.
confirmed that use of these criteria has high sensitivity (88.7%)
and specificity (77.5%) (Yin et al., 2012) for the diagnosis of Mp
pneumonia if four or more of the proposed factors are present.
The six factors are as follows: (i) <60 years of age; (ii) absence
of, or only minor, underlying diseases; (iii) stubborn cough; (iv)
adverse findings on chest auscultation; (v) absence of sputum or
identifiable etiological agent by rapid diagnostic testing; and (vi)
a peripheral white blood cell count<10,000/μL.
SPECIAL CIRCUMSTANCES
Latent respiratory infection/asymptomatic carrier
Mp pneumonia is a one of the leading causes of CAP, and it may
exacerbate symptoms of underlying asthma (Nisar et al., 2007),
especially in up to 25% of children with wheezing (Henderson
et al., 1979); it was identified in 20% of exacerbations in asth-
matic children requiring hospitalization and in 50% of chil-
dren experiencing their first asthmatic attack (Biscardi et al.,
2004). Spuesens et al. demonstrated that Mp was carried at
high rates in the upper respiratory tracts of healthy children
(Spuesens et al., 2013). However, Cunningham et al. could not
confirm the relationship between asthma symptoms and Mp
infection in children aged 9–11 years (Cunningham et al., 1998).
Another study showed that most Mp patients, positive by PCR,
had respiratory symptoms; that Mp DNA might be detected
several months after acute infection; and that asymptomatic
carriage of Mp is uncommon even after the outbreak period
(Nilsson et al., 2008).
Especially for adults, to our knowledge, there have been few
reports regarding the frequency of latent respiratory infection
with Mp. Wadowsky et al. reported that tests of 473 respira-
tory specimens by culture, PCR, or both identified only four
episodes (0.8%) ofMp-associated illness in adolescents and adults
(n = 491) with persistent cough (Wadowsky et al., 2002). Thus,
the frequency of the Mp carrier state or the bacterial load might
be different between children and adults, or between healthy and
asthmatic individuals. Indeed, our epidemiological data through-
out the year demonstrated that among admitted adult patients
with diverse respiratory diseases, including acute exacerbation of
idiopathic interstitial pneumonia (n = 15), pneumonia (n = 43),
asthma attack (n = 14), and exacerbation of COPD (n = 11),
there were 4 cases of definite Mp pneumonia as diagnosed by a CF
antibody titer increased ≥ 4-fold or passive particle agglutination
test≥ 640, but with no identifiable Mp in the throat/nasopharynx
or sputum by both culture and PCR methods (Kurai et al.,
2013b) (Figure 7). This might reflect the fact that Mp acted
only to trigger the lower respiratory symptoms or pneumonia,
but the bacterial load was low, resulting in a latent respira-
tory infection or even in Mp pneumonia, especially in adult
patients.
Macrolide-resistant Mp pneumonia
Macrolide-resistant Mp emerged and was widespread in East Asia
after 2000. The reasons for the regional differences in macrolide-
resistant Mp have not been elucidated. The A2063G mutation
has been found to be most prevalent in macrolide resistant
Mp isolates, followed by the A2064G mutation; these mutations
are associated with increased minimum inhibitory concentra-
tions to macrolides, including erythromycin, azithromycin, and
clarithromycin.
Previous studies revealed that macrolide-resistant Mp pneu-
monia patients had a prolonged fever compared to those with
macrolide-susceptible Mp pneumonia, in both children and
adults (Suzuki et al., 2006; Cao et al., 2010; Pereyre et al.,
2012; Yoo et al., 2012). In patients with macrolide-resistant
Mp pneumonia, clinical findings, including symptoms, labora-
tory results, radiology, the complication of respiratory failure,
and mortality were not different from those of patients with
macrolide-susceptible Mp pneumonia. However, persistent fever
over 48 h after initiation of macrolide may point to the presence
of macrolide-resistant Mp (Miyashita et al., 2013).
FIGURE 7 | Epidemiological data of adult patients admitted
throughout the year to Kyorin University Hospital for respiratory
disease. Diagnoses consisted of acute exacerbation of idiopathic interstitial
pneumonias (n = 15, 18%); pneumonia (n = 43, 52%), including 4 cases of
definite Mp pneumonia diagnosed by CF antibody titer of ≥ four-fold or
passive particle agglutination test ≥640; asthma attack (n = 14, 17%); and
exacerbation of COPD (n = 11, 13%).
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Fulminant Mp pneumonia
Mppneumonia is usually mild and rarely fatal. The severity ofMp
pneumonia seems to depend on the Mp bacterial load rather than
the Mp genotype (Nilsson et al., 2010). Among patients with Mp
pneumonia, 3–4% develop severe, life-threatening illness with
respiratory failure and acute respiratory distress syndrome (Holt
et al., 1977; Fraley et al., 1979; Koletsky andWeinstein, 1980; Chan
and Welsh, 1995; Ito et al., 1995; Takiguchi et al., 2001; Tsuruta
et al., 2002; Miyashita et al., 2007). Two groups (Chan andWelsh,
1995; Miyashita et al., 2007) reported that the delayed admin-
istration of adequate antimicrobials was noted in severe Mp
pneumonia patients, at an average of 9.3 or 15 days, respectively,
which may be the most important reason for the development of
fatal respiratory failure. However, some cases who had adequate
antimicrobials within 3 days after the onset of the disease pro-
gressed to respiratory failure (Miyashita et al., 2007). Izumikawa
et al. reviewed 52 Japanese cases of fulminant Mp pneumonia
(Izumikawa et al., 2014), which was defined as the presence of
Mp pneumonia with hypoxia, and reported that no apparent risk
factors for fulminant Mp pneumonia were identified, but con-
cluded that initial inappropriate use of antimicrobials may be a
risk factor.
RADIOLOGICAL FEATURES
A wide spectrum of findings on thin-section CT have been
reported, such as ground glass opacities (GGO), consolidation,
bronchial wall thickening, centrilobular nodules, interlobular
septal thickening, pleural effusion, mosaic attenuation, air trap-
ping, and lymphadenopathy (Kim et al., 2000; Reittner et al.,
2000; Chiu et al., 2006; Lee et al., 2006; Miyashita et al., 2009).
Each of those radiological findings are non-specific, butMiyashita
et al. reported that bronchial wall thickening and centrilobu-
lar nodules on thoracic CT would be a clue to the diagnosis
(Miyashita et al., 2009). Figure 8 shows typical HRCT findings
such as consolidation with air bronchograms surrounded by a
crazy paving appearance (A), consolidation with reticular shadow
(B), consolidation with GGO (C), GGO with interlobular sep-
tal thickening (D), crazy paving appearance (E), bronchial wall
thickening with centrilobular nodules (F), diffuse centrilobular
nodules.
DIAGNOSTIC METHODS
CULTURE
Culture is the “gold standard” method for diagnosis of Mp infec-
tion and is essential for further analysis, including drug resistance
tests, although it is useless as a rapid diagnostic method because
of the low sensitivity and the need for incubation for several weeks
in specialized culture medium.
SEROLOGICAL METHODS
There are many diagnostic serological tests, although these
serological tests and their interpretations are not standardized.
Serological methods, such as complement fixation (CF), passive
agglutination (PA), and detection of IgG and IgM by enzyme
immunoassays (EIA) were conventionally used for diagnosis of
Mp infection. CF tests measure IgM and IgG antibodies together,
but these antibodies are non-specific. The target for PA tests
FIGURE 8 | The HRCT findings of Mp pneumonia are characterized as
(A) consolidation with air bronchogram surrounded by a crazy paving
appearance, (B) consolidation with reticular shadow, (C) consolidation
with GGO, (D) GGO with interlobular septal thickening, crazy paving
appearance, (E) bronchial wall thickening with centrilobular nodules,
(F) diffuse centrilobular nodules.
FIGURE 9 | Model E, the clarithromycin (CAM)-treated murine model.
Just before intratracheal challenge (IT) with Mp antigen, mice were divided
into 3 treatment regimen groups. All were orally treated once a day with
CAM (12.5mg/kg/day or 25mg/kg/day) or vehicle for 2 consecutive weeks.
CAM, clarithromycin; IT, intratracheal challenge; P.O, per os; BALF, bronchial
alveolar lavage fluid.
was mainly IgM antibody, but seemed to be less specific for Mp
than the Mp-specific IgM enzyme-linked immunosorbent assays
(ELISA) (Barker et al., 1990).
Paired sera for CF, PA andMp-specific IgG EIA tests are widely
used for epidemiological studies and are regarded as a standard
method for diagnosis. The definition of Mp infection was based
on the serological finding of a four-fold titer rise (in CF or PA
tests), and seroconversion or a significant increase, of Mp IgG
during the convalescent phase compared with the acute phase.
Single high titers were also considered markers of Mp infection,
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and the difference of cut-off titer used in various studies has a
great impact on the resulting epidemiological data. If either CF
titers are higher than 1:64 or 1:128, or PA titers are higher than
1:320 or 1:640, a diagnosis of Mp infection was made (Marston
et al., 1997; Dorigo-Zetsma et al., 1999; Templeton et al., 2003;
Beersma et al., 2005; Kim et al., 2007). Measurement of Mp-
specific IgM antibodies by EIA has been commercially available
for the diagnosis of Mp infection during the early phase. Beersma
et al. (2005) reported that twelve IgM EIA assays showed various
diagnostic yields when compared to PCR-proved Mp pneumo-
nia as the reference standard. The sensitivity and specificity of
these IgM EIA assays were 35–77% and 49–100%, respectively,
and those assays had low diagnostic yields within a week after
initial onset. Mp-specific IgM (EIA) assays were less useful for
adults with autoantibodies or other infectious diseases, such as
Epstein-Barr virus, Streptococcus pyogenes and Treponema pal-
lidum, because of the tendency of these to produce false positives
(Petitjean et al., 2002; Beersma et al., 2005).
NUCLEIC ACID AMPLIFICATION METHODS
Polymerase chain reaction (PCR)-based methods using respira-
tory samples have been developed for rapid Mp diagnosis. This
application was limited to select hospitals because complicated
procedures and expensive systems are required. Diagnosis of Mp
infection using PCR was inconsistent among individual stud-
ies because of many factors, as follows: patients’ ages; intervals
between onset of symptoms and sampling specimens; types of
specimen sampling methods; target lesion of PCR; and techni-
cal procedures (Raty et al., 2005; Loens et al., 2009; Thurman
et al., 2009). He et al. showed that PCR-based diagnosis was supe-
rior to IgM-based diagnosis in Mp-infected patients less than 3
years of age; an immature immune response to Mp may explain
this discrepancy (He et al., 2013). A meta-analysis of PCR-based
diagnosis for Mp infection showed that sensitivity and specificity
were 0.62 (95% CI, 0.45–0.76) and 0.96 (95% CI, 0.93–0.98),
respectively (Zhang et al., 2011).
As for Mp pneumonia, PCR and serological diagnosis had
good concordance in adult patients; PCR-based diagnosis had
lower sensitivity (66.7%) compared to serological diagnosis as the
reference standard. This result was consistent with those in other
reports on Mp CAP in adults (Pitcher et al., 2006; Martinez et al.,
2008; Qu et al., 2013). The sensitivity and specificity of PCR-based
diagnosis in these studies were 40.7–66.7% and 88.8–98.5%,
respectively; the reference standard was a serological diagnosis
(Table 3).
Loens et al. and Raty et al. described that if a sputum sample
is available, it might be better for Mp detection in patients with
Mp pneumonia than nasopharyngeal or oropharyngeal swabs
(Raty et al., 2005; Loens et al., 2009). A nucleic acid amplifi-
cation method, termed loop-mediated isothermal amplification
(LAMP), was introduced in order to improve the complicated sys-
tem of PCR, and LAMP results were concordant with PCR results
(Saito et al., 2005).
In the early phase of the illness, the preferred diagnostic meth-
ods seemed to be culture and nucleic acid amplification. In the
late phase, those methods are useless because of the low Mp
load in the airways; furthermore, regarding the limited value of
Table 3 | Comparison of diagnostic methods.
Sensitivity (%) Specificity (%) Comment
Culture 55.6 94.9 Isolation of Mp is
slow and
insensitive, and
therefore is not
recommended for
routine use.
PCR 40.7–66.7 88.8–98.5 Rapid diagnosis is
possible, but is
costly and
complicated
procedures are
needed. Therefore
PCR-based
diagnosis is limited
to a few
laboratories.
Serology
IgM
7.4–77 49–100 Diagnostic yields
for Mp IgM tests
were variable,
according to
available assays.
Use of paired sera
for CF, PA or IgG
analysis is
preferable.
(Pitcher et al., 2006; Martinez et al., 2008; Qu et al., 2013). Most of data are from
lower respiratory infections in adults, including pneumonia patients.
single serum samples, paired serological examinations would be
required for diagnosis (Thurman et al., 2009). In conclusion, no
reliable simple method exists for accurate diagnosis; therefore, we
recommend the culture and nucleic acid amplification in the early
phase, and serological examinations in the late phase, respec-
tively, especially in the patients with severe pneumonia and/or
who satisfied four or more of the proposed factors as described
in “General aspects.”
EXTRAPULMONARY MANIFESTATIONS
Although direct invasion, neurotoxin production, or an immune-
mediated process have been proposed, the mechanisms under-
lying extrapulmonary manifestations of Mp infection remain
largely unknown. These are diverse (Foy et al., 1983; Lind,
1983; Narita, 2010) and include central nervous system diseases
such as encephalitis, aseptic meningitis, polyradiculitis, cerebellar
ataxia, and myelitis (Guleria et al., 2005; Tsiodras et al., 2006);
cardiovascular diseases such as pericarditis, endocarditis, and
myocarditis; the dermatological diseases Stevens-Johnson syn-
drome, erythema multiforme (Cherry, 1993; Lamoreux et al.,
2006), erythema nodosum, anaphylactoid purpura, and acute
urticaria (Kano et al., 2007); hematological diseases includ-
ing autoimmune hemolytic anemia (cold agglutinin disease),
hemophagocytic syndrome, disseminated intravascular coag-
ulation, and thrombocytopenic purpura (Cassell and Cole,
1981); inflammatory diseases including conjunctivitis, iritis
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FIGURE 10 | Sequential analysis of bronchial alveolar lavage fluid at days 2, 4, 7, and 14 after intratracheal challenge. (A) No significant difference in the
neutrophil count was seen. (B) Number of lymphocytes in the CAM-treated groups was significantly suppressed dose-dependently at days 4 and 7.
FIGURE 11 | Lymphoplasmacytic infiltration within the PBVA was
markedly suppressed in the (A) CAM50 group as compared with the
(B) vehicle group. PBVA, peribronchovascular area.
(Salzman et al., 1992), uveitis (Weinstein et al., 2006), and
arthritis (Franz et al., 1997); and otitis media. The presence of
these extrapulmonary manifestations is itself evidence of human
immune system interaction with Mp.
TREATMENT
The recommended therapy for microbiologically confirmed Mp
pneumonia is use of macrolides (CAM: clarithromycin and AZM:
azithromycin) or tetracyclines, and fluoroquinolones are an alter-
native choice (Lim et al., 2009). However, neither tetracyclines nor
fluoroquinolones are recommended for young children under 8
years of age because of their adverse effects, such as permanent
yellowing or graying of the teeth, and abnormalities of articular
cartilage and the QT interval. Therefore, macrolide-resistant Mp
pneumonia is a major concern for children who require treat-
ment. Several studies showed that macrolide-resistant Mp was
susceptible to tetracycline and fluoroquinolone in vitro (Eshaghi
et al., 2013; Hong et al., 2013). Minocycline or doxycycline,
both tetracyclines, quickly decreased the loads of macrolide-
resistant Mp and were effective against the resistant pathogen
in humans. Okada et al. showed that tosufloxacin, a fluoro-
quinolone, seemed to be inferior to minocycline or doxycy-
cline in clinical use (Okada et al., 2012). However, macrolides
have an immunomodulatory or bacteriological effects even on a
mouse model with macrolide-resistant Mp strain (Kurata et al.,
2010). Therefore, even in the area of high resistant to macrolides
such as Japan, JRS recommend the use of macrolides as first
therapy for Mp pneumonia together with the use of method
for differential diagnosis of atypical pneumonia and bacterial
pneumonia.
Infectious Diseases Society of America (IDSA) and the
American Thoracic Society (ATS) joint guidelines on adult CAP
described that patients with CAP should be treated for a min-
imum of 5 days (level I evidence), and most patient become
clinically stable within 3–7 days, so longer durations of therapy
are rarely necessary (Mandell et al., 2007), but JRS guidelines does
not refer to the optimal duration of the treatment. Smith CB et al.
showed that tetracycline and erythromycin improve symptoms in
adult volunteers who experimentally infected with Mp, but recur-
rence of Mp pneumonia was noted after completion of 7 days
treatment with tetracycline (Smith et al., 1967).
Thus, the optimal antimicrobial dosage and duration are not
clear; however, 10–14 days of therapy is generally recommended.
Effective treatment of Mp pneumonia shortens the duration
of fever and might prevent aggravation (Denny et al., 1971;
Izumikawa et al., 2014).
IMMUNOMODULATIVE EFFECTS OF MACROLIDE THERAPY
Macrolides have direct effects on neutrophil function and
production of cytokines involved in inflammation cascades
(Zarogoulidis et al., 2012).
For Mp infections, 14- or 15-membered ring macrolides usu-
ally are considered the first-line agents, which are well known
for anti-inflammatory, immunomodulative effects (Wales and
Woodhead, 1999). CAM is a macrolide with a 14-atom lac-
tone ring, and attenuation of inflammatory responses has been
reported in both animal models of Mp pneumonia (Kurata et al.,
2010) and in humans with respiratory diseases (Kudoh et al.,
1998).
To examine the immunomodulative effects of CAM, mice in
model E (Figure 1E) were treated with three different regimens,
as follows: (Figure 9) orally with CAM at two doses (CAM12.5
group: 12.5mg/kg/day or CAM50 group: 50mg/kg/day); or with
vehicle (methylcellulose), all at 1.5 h just before IT with Mp
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FIGURE 12 | There were fewer cytokines in the CAM50-treated
group (50mg/kg/day orally), compared with the vehicle
group. Only RANTES was significantly suppressed in the
CAM50 group, at day 2 (p = 0.025). BALF: bronchoalveolar
lavage fluid. RANTES: regulated on activation, normal T cell
expressed and secreted. ∗p < 0.05.
antigen (day 0) (Saraya et al., 2007a; Saraya and Goto, 2008).
Just before and after IT, the 3 groups were orally treated
once a day with CAM or vehicle for 2 consecutive weeks.
On BAL cell differential count analysis, there were no signif-
icant differences in the neutrophil count among the 3 groups
in any phase (Figure 10A). However, the number of lympho-
cytes in the CAM-treated groups was significantly suppressed
in a dose-dependent manner at day 4, and the effect was still
recognized at day 7 (Figure 10B). Pathological assessment at
day 4 post-IT revealed that the lymphoplasmacytic infiltra-
tion within the PBVA was markedly suppressed in the CAM50
group (Figure 11A), as compared with that of the vehicle group
(Figure 11B).
BALF cytokines in the CAM50 group seemed to be lower
than those of the vehicle group, and only RANTES was signif-
icantly suppressed in the former group, at day 2 (p = 0.025)
(Figure 12). Those data suggested that oral administration of
CAM has immunomodulative effects on lung inflammation even
in the early phase of Mp pneumonia. This dose-dependent
immunomodulative effect of CAMwas consistent with previously
reported results of a study using an experimental Mp pneumonia
mouse model (Tagliabue et al., 2011).
STEROIDS AS ADDITIVE THERAPY
Animal experimental models (Tagliabue et al., 2008; Hirao
et al., 2011) showed that corticosteroids down-regulate the host
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immune response. Furthermore, treatment with the combina-
tion of clarithromycin and a corticosteroid, compared to clar-
ithromycin alone, resulted in a significantly greater reduction
of IL-12 p40 and RANTES (Tagliabue et al., 2008). Izumikawa
et al. (2014) reported that a majority of human patients with
fulminant Mp pneumonia had improved respiratory function
on steroid treatment within 3–5 days, which was considered to
be an effect of suppressing hyperactivated cellular immunity.
Radisic et al. reported on the suppressing effects of steroids on
the cell-mediated immune response (Radisic et al., 2000), and
that acute respiratory distress syndrome (ARDS) secondary to
Mp infection is a lymphoid cellularity ARDS caused by a harm-
ful, “over-reacting” cell-mediated immune response, which could
potentially be tapered by the use of steroids. Thus, steroid use
would be the preferable treatment of patients with fulminant Mp
pneumonia in light of the immune response.
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